A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7088 (2006.01) A61K 9/14 (2006.01) A61K 9/72 (2006.01) A61K 31/711 (2006.01) A61K 31/7125 (2006.01) A61K 31/713 (2006.01) A61P 11/00 (2006.01) C12N 15/113 (2010.01)
Patent
CA 2594675
A preventive, therapeutic or improving agent for chronic obstructive pulmonary disease (COPD), cystic fibrosis or pulmonary hypertension is provided. More specifically, the invention is directed to (1) a preventive, therapeutic or improving agent for chronic obstructive pulmonary disease (COPD), cystic fibrosis or pulmonary hypertension comprising an NF-.kappa.B decoy as an active ingredient; (2) the NF-.kappa.B decoy being an oligonucleotide having a binding sequence GGGRHTYYHC (wherein R represents A or G, Y represents C or T, and H represents A, C or T); (3) the oligonucleotide in which the NF-.kappa.B binding sequence is GGGATTTCCC or GGGACTTTCC; (4) the NF-.kappa.B decoy being the oligonucleotide represented by SEQ ID NO: 3; (5) the NF-.kappa.B decoy being a double-stranded oligonucleotide; (6) the NF-.kappa.B decoy being administrated in the form of a fine powder; and (7) the NF-.kappa.B decoy fine powder being a dry powder.
L'invention porte sur un agent préventif, thérapeutique ou améliorant destiné à traiter les maladies pulmonaires obstructives chroniques, la fibrose cystique ou l'hypertension pulmonaire. L'invention concerne plus particulièrement (1) un agent préventif, thérapeutique ou améliorant destiné à traiter les maladies précitées et comprenant un leurre NF-.kappa.B utilisé comme ingrédient actif; (2) le leurre NF-.kappa.B étant un oligonucléotide possédant une séquence de liaison GGGRHTYYHC (dans laquelle R représente A ou G, Y représente C ou T et H représente A, C ou T); (3) l'oligonucléotide dans lequel la séquence de liaison NF-.kappa.B est GGGATTTCCC ou GGGACTTTCC; (4) le leurre NF-.kappa.B étant l'oligonucléotide représenté par SEQ ID NO: 3; (5) le leurre NF-.kappa.B étant un oligonucléotide double brin; (6) le leurre NF-.kappa.B étant administré sous forme d'une poudre fine et (7) la poudre fine du leurre NF-.kappa.B étant une poudre sèche.
Gemba Takefumi
Otsu Kunimiki
Saito Tetsu
Anges Mg Inc.
Smart & Biggar
LandOfFree
Therapeutic agent for chronic obstructive pulmonary disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agent for chronic obstructive pulmonary disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agent for chronic obstructive pulmonary disease... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1431335